









Markets
/
Stocks
/
nasdaq-mnpr
/

Monopar Therapeutics Inc

MNPR

View Detailed Chart

40.690USD

-0.490-1.19%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

248.83MMarket Cap

LossP/E TTM



Monopar Therapeutics Inc

40.690

-0.490-1.19%

Overview Company Financials

Financials

Intraday

30m

Today

-1.19%

5 Days

-9.52%

1 Month

+12.25%

6 Months

-6.57%

Year to Date

+84.95%

1 Year

+1072.62%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 6 analysts

BUY

Current Rating

63.800

Target Price

56.80%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Monopar Therapeutics Inc

MNPR

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(6)

Neutral(2)

Buy(3)

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.253

Neutral

RSI(14)

48.940

Neutral

STOCH(KDJ)(9,3,3)

14.631

Sell

ATR(14)

2.896

Low Volatility

CCI(14)

-109.178

Sell

Williams %R

89.319

Oversold

TRIX(12,20)

0.916

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

42.192

Sell

MA10

44.127

Sell

MA20

42.535

Sell

MA50

37.471

Buy

MA100

37.507

Buy

MA200

31.990

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.

Ticker SymbolMNPR

CompanyMonopar Therapeutics Inc

CEODr. Chandler D. Robinson, M.D.

Websitehttps://www.monopartx.com/